In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PerSeptive Biosystems Inc.

Division of Thermo Fisher Scientific Inc.

Latest From PerSeptive Biosystems Inc.

EngeneOS Inc.

Boston-area start-up engeneOS Inc. aspires to build molecular machines with starting materials that come from nature. The firm aims to take advantage of the the fact that proteins and nucleic acids have evolved highly specific capabilities over thousands of years. Management sees them as components that can be catalogued, combined and harnessed to carry out new tasks.

BioPharmaceutical Strategy

Big Foot: Celera Steps into the Genomic Market

PE Corp. created Celera to exploit its high-productivity new sequencer, the Prism 3700, and build a broad set of proprietary genomic databases. The move instantly boosted sales of the new sequencer, paying for the expensive start-up in increased revenues to PE's PE Biosystems division and a dramatic increase in market value. Unlike its genomic database competitors, Celera won't charge subscribers royalties and milestones for successful use of the data. To encourage broad and continuing use of the system it hopes will become the industry standard, it plans to make money largely on subscription fees and enlarging its client base, not reach-through rights. But novel genetic data is just the hook for catching clients--Celera hopes to keep them subscribing with a program of continuous annotations and a set of bioinformatics tools that enable a level of in silico experimentation once requiring highly expensive in vitro and in vivo studies. But a raft of new and older competitors stand in the way of its bioinformatics ambitions.

BioPharmaceutical Strategy

Creator Complex

With $5 million in funding from PE Corp. and another $30-$35 million to be raised through limited partners, Noubar Afeyan, PhD, the founder of PerSeptive Biosystems, has formed a new seed fund, Newcogen, to invest in life sciences and information technologies. The new fund will create companies around concepts, acting as a cross between a seed stage fund, an incubator, and an entrepreneur-in-residence program.

BioPharmaceutical Business Strategies


Combinatorial chemistry company Chemicus focuses on bottlenecks in lead optimization in the drug discovery process. Chemicus claims that its abacus system makes larger amounts of similar compounds necessary for evaluating "hits" further down the drug discovery line.

BioPharmaceutical Research and Development Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Thermo Fisher Scientific Inc.
  • Senior Management
  • Noubar B Afeyan, PhD, Chmn. & CEO
    Thomas G Ruane, SVP & CFO
    John F Smith, Pres.
    Fred E Regnier, CTO
  • Contact Info
  • PerSeptive Biosystems Inc.
    Phone: (508) 383-7700
    500 Old Connecticut Path
    Framingham, MA 01701